MDMridu Dudeja

Mridu Dudeja

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Mridu Dudeja has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Ayan Kumar Das

    Department of Microbiology, Hamdard Institute of Medical Sciences and Research and Associated HAHC Hospital, New Delhi, India

    3 shared publications
  • Kailash Chandra

    Department of Biochemistry, Hamdard Institute of Medical Sciences and Research and Associated HAHC Hospital, New Delhi, India

    2 shared publications
  • Santosh Joshi

    Research and Development, Hamdard Laboratories (Medicine Division), Ghaziabad, Uttar Pradesh, India

    2 shared publications
  • Sumeera Banday

    Department of Respiratory Medicine, Hamdard Institute of Medical Sciences and Research and Associated HAHC Hospital, New Delhi, India

    2 shared publications
  • Arjun Dang

    Department of Hematology, Dr. Dang’s Lab Pvt Ltd., New Delhi, India

    1 shared publication
  • Asad Mueed

    R & D Hamdard Laboratories (Medicine Division) Ghaziabad Uttar Pradesh India

    1 shared publication

Latest Publications

  • Open Access

    Assessment of Conventional and Molecular Methods in the Routine Management of Tuberculosis in a High Tuberculosis Burden Setting

    by Rushna Wazahat, Mehvash Haider, Debasish Chattopadhya, Mridu Dudeja

    Background and aims: India is a high-burden tuberculosis region and a drug-resistance hotspot. Despite numerous reports of pulmonary tuberculosis (PTB) cases, there needs to be more literature available on the importance of diagnostic methods in the case of extrapulmonary tuberculosis (EPTB). A prospective study was carried out from July 2017 to June 2018 to compare the efficacy of conventional and molecular methods in detecting PTB and EPTB cases. Methods: 1000 presumptive PTB and 412 EPTB cases were subjected to staining (Ziehl-Neelson and fluorescent staining), culture, GeneXpert, and line probe assay. Results: The sensitivity, specificity, and strength of association, i.e., kappa (k) value of LED-FM, ZN, and GeneXpert, were calculated using standard formulae using solid culture as the gold standard. The sensitivity of GeneXpert in smear-positive/culture-positive PTB was comparable with the smear-negative/culture-positive PTB cases (95.7% Vs. 87.5%) with an overall sensitivity and specificity of 90.5% and 90.1% in EPTB cases, respectively. However, sensitivity was lower for pleural fluid (75%) and tissues (85.7%). In pulmonary instances, 10% (6.7% RIF + INH resistant and 3.3%INH monoresistant) drug resistance was observed, and no drug resistance was found in extra-pulmonary samples. Conclusion: Among conventional methods, Fluorescent staining is more sensitive than Ziehl-Neelson (ZN) staining, while the sensitivity of GeneXpert varies w.r.t type of sample using culture positivity as the gold standard. The present study suggests the promotion of universal DST for all individuals with TB to control drug-resistant tuberculosis.


  • Open Access

    Phenotyping of lymphocyte subsets, Th-1/Th-2 cytokines and other parameters in high-risk contacts of SARS-CoV-2

    by Kailash Chandra, Ayan Kumar Das, Sumeera Banday, Neha Dhyani, Bhumika Upadhyay, Arjun Dang, Santosh Joshi, Mridu Dudeja

    Background: The information on the pathophysiology of infection in high-risk contacts of SARS-CoV-2 is limited. Aims: The aim of the present study was to assess the various factors and their elucidation in the protection of SARS- CoV-2 infection in high-risk contacts. Settings and Design: Cross-sectional descriptive clinical study. Materials and Methods: A total of 136 subjects were recruited in the present study including 100 high-risk subjects and 36 control subjects. Out of 100 high-risk subjects, 44 subjects were found positive for SARS-CoV-2 RNA. Further, absolute blood counts of total T-cells (CD3+), T-helper cells (CD4+), T-cytotoxic cells (CD8+), B lymphocytes (CD19+) Natural Killer (NK) Cells (CD16+, CD56+), cytokines, and other parameters were measured in the samples of study subjects. Statistical Analysis Used: The continuous variables were analyzed by unpaired ‘t’ test, analysis of variance and ‘Tukey test’ for multiple comparisons. Results: A significant reduction of total leukocyte counts and absolute lymphocyte count was found in the acute SARS-CoV-2 positive group as compared to control group (p < 0.05). A significant decrease of T-cytotoxic, B-cells, and NK cells were found in acute SARS-CoV-2 positive subjects as compared to control groups. Conclusion: The findings of this study may augment our knowledge about the pathogenesis of SARS-CoV-2 infection that could help in making future strategies to control its infection.

  • Efficacy of polyherbal formulations for prevention of COVID‐19 infection in high‐risk subjects: A randomized open‐label controlled clinical trial

    by Kailash Chandra, Ayan Kumar Das, Sumeera Banday, Naushad Ali Rana, Mohini Arora, Sonal Jain, Farzana Islam, Shashank Agarwal, Varun Kashyap, Santosh Joshi, et al.

    COVID‐19 is arguably the biggest health crisis the world has faced in the 21st century. Therefore, two of the polyherbal formulations, Infuza and Kulzam were assessed for the prevention of COVID‐19 infection as a repurposed medication. Four hundred seven high‐risk subjects were recruited in the present open‐label randomized controlled clinical trial for eligibility. After assessment for eligibility, remaining 251 subjects were randomized to the test and control groups. Further, 52 high‐risk subjects in Infuza, 51 in Kulzam, 51 in Infuza & Kulzam and 53 in control group completed the 14 days of intervention/assessment. The phenotyping of lymphocytes at baseline (0 day) and after 14 days of treatment was carried out by flow cytometry assays. A total of 15.09% high‐risk subjects in control group turned positive as compared to only 7.69% in Infuza, 3.92% in Kulzam and 1.96% in Infuza & Kulzam groups. The rate of conversion to COVID‐19 infection in Infuza & Kulzam group was minimal and statistically significant as compared to control group (p0.017). No significant changes in phenotype of lymphocytes (T, B, NK cells), absolute lymphocyte count and cytokine levels were found in study groups. However, there was a decreasing trend of hs‐CRP level in high‐risk subjects after intervention of polyherbal formulations for 14 days. The combination of Infuza and Kulzam may synergistically prevent COVID‐19 infection in high‐risk subjects of COVID‐19.


  • Open Access

    Genotypic characterization of vancomycin-resistant Enterococcus causing urinary tract infection in northern India

    by Ayan Kumar Das, Mridu Dudeja, Sunil Kohli, Pratima Ray

    Background & objectives: Infections caused by vancomycin-resistant Enterococci are difficult to treat given the limited therapeutic alternatives. Different gene clusters are known to confer vancomycin resistance. vanA and vanB genes are transferable and are clinically relevant. This cross-sectional study aimed to identify the vancomycin-resistant genotypes in the strains causing urinary tract infection and also to test the in vitro efficacy of linezolid and pristinamycin against the vancomycin-resistant isolates. Methods: Antimicrobial resistance profile of 118 enterococcal isolates was evaluated. Minimum inhibitory concentration of vancomycin, teicoplanin and high-level gentamicin (HLG) was determined by micro broth dilution. The vancomycin-resistant isolates were tested against linezolid and pristinamycin by micro-broth dilution and E strip method. The presence of vancomycin-resistant genes was detected by multiplex polymerase chain reaction and was sequenced and analyzed. Results: Most commonly isolated species were Enterococcus faecalis (76.9%) and Enterococcus faecium (16.9%). It was found that 43 per cent of the isolates were resistant to HLG and 16.9 per cent to vancomycin. Higher resistance was seen against fluoroquinolones, erythromycin, tetracycline and β-lactam drugs. However, 5.08 per cent strains were resistant to tigecycline. All vancomycin-resistant strains were sensitive to pristinamycin and one was resistant to linezolid. vanA and vanB gene were found in 15 and five isolates, respectively. The gene sequences were submitted to NCBI gene bank and accession numbers were obtained. Interpretation &conclusions: The present study showed prevalence of vanA and vanB genes carrying Enterococcus in a tertiary care centre in north India. The emergence of resistance against drugs such as tigecycline and linezolid is a topic of concern as it will be a therapeutic challenge for physicians.


  • Open Access

    PCR amplification of shorter fragments from thedevR(Rv3133c) gene significantly increases the sensitivity of tuberculosis diagnosis

    by Soumitesh Chakravorty, Divya Pathak, Mridu Dudeja, Sagarika Haldar, M. Hanif, Jaya Sivaswami Tyagi

    This study was designed to assess the vital issue of gene target length and PCR assay performance in relation to the detection of Mycobacterium tuber